Skip to main content

Table 2 Fold change (median) of genes after 4 weeks intervention with a mixture of c9t11 and t10c12 CLA, c9t11 CLA, and t10c12 CLA compared to control (LA) according to realtime PCR verification.

From: Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARγ2 P12A polymorphism: a double blind, randomized, controlled cross-over study

 

MIX

C9T11 CLA

T10c12 CLA

 

Gene symbol [NCBI RefSeq]

all

Pro

Ala

all

Pro

Ala

all

Pro

Ala

 

Fatty acid transport and metabolism

         

PPARγ dependency

   ABCA9 [NM_080283.3]

-1.3*

-1.3*

    

-1.4*

  

n/a

   LDLR [NM_000527.3]

1.2**

1.8**

    

1.5**

1.5**

 

↑[85]

   CD36 [NM_001001547.1]

   

-1.2*

 

-1.6*

-1.3*

 

-1.2*

↑[65, 86]

   LIPE [NM_005357.2]

  

1.96†

     

1.8†

↑[23]

   CA3 [NM_005181.2]

      

-2.0**

-2.0*

 

n/a

   FASN [NM_004104.4]

 

1.5*

    

1.2*

1.4*

 

↑[87]

   SCD [NM_005063.4]

  

1.3*

   

1.5*

 

1.9*

↑[34, 88]

   FADS1 [NM_013402.3]

1.6*

1.6*

       

n/a

Transkription factors

          

   PPARG [NM_138711.3]

 

-1.4**a

1.3 b

       

   NFAT5 [NM_138713.2]

-1.5*

-1.6*

    

-1.6*

 

-1.9†

n/a

   CREB5 [NM_182899.3]

      

-1.5*

 

-1.9†

n/a

   EBF1 [NM_024007.3]

 

-1.5†

       

↑[89]

Adipokines

          

   ADIPOQ [NM_004797.29]

  

1.6†

     

1.5†

↑[90, 91]

   LEP [NM_000230.2]

 

-1.2 a

1.7†b

      

↓[92]

   NAMPT [NM_005746.2]

        

-1.6*

= [62]

   THBS1 [NM_003246.2]

   

1.5**

1.3*

1.5*

   

↓[64] ↑[65]

Insulin signaling

          

   IGF1 [NM_001111284.1]

 

-1.5†

    

-1.2**

-1.2*

 

↓ [93]

   SLC2A4 [NM_001042.2]

1.3*

 

1.5†

      

↑[94]

   SORBS1 [NM_001034954.1]

 

-1.2*

       

↑[74]

   PIK3R1 [NM_181523.1]

 

-1.6†

       

↑[95]

Others

          

   HPGD [NM_000860.3]

-1.3**

 

-1.4**

     

-1.6*

See text

   API5 [NM_006595.2]

      

-1.3†

 

-1.5*

n/a

   CD74 [NM_001025158.1]

 

1.2*

       

n/a

   UCP2 [NM_003355.2]

1.14*

       

1.8†

↑[79]

   IL6ST [NM_175767.1]

-1.3*

     

-1.5†

 

-1.8†

n/a

  1. Comparison of CLA interventions and control (Wilcoxon test): *p < 0.05; **p < 0.001; † marks values with a tendency p ≤ 0.1 and more than +/- 1.5 fold change. Letters a and b indicate significant differences (p < 0.05) between effects in PPARγ2Pro12Pro (Pro; n = 23) and PPARγ2Ala12Ala (Ala; n = 11) carriers after the CLA mixture supplementation (Mann-Whitney U test).